This year’s edition of Pricing and Market Access Outlook, our first as IQVIA, identifies a trend towards models
(Reuters) – A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
When Spark Therapeutics announced last week an $850,000 price for its gene therapy Luxturna, some critics held it up as the latest example of an expensive new treatment that could break the bank for the healthcare system. But at the J.P. Morgan Healthcare conference this week, it was clear that sentiment is rapidly changing. https://www.fiercepharma.com/financials/payers-point-to-spark-s-gene-therapy-as-a-model-for-innovative-pricing-plans
Congress hasn’t made any progress on drug pricing legislation, but that hasn’t stopped the government from acting. Now, FDA Commissioner Scott Gottlieb has unveiled yet another move to step up competition in the generics business. http://www.fiercepharma.com/regulatory/fda-advances-price-competition-push-by-prioritizing-certain-generic-applications
FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Recently, the agency he oversees took some unusual steps to back up those statements with action. Last week, the FDA approved the use […] http://www.xconomy.com/san-diego/2017/08/21/on-drug-pricing-fda-backs-up-its-calls-for-increased-competition/
BRUSSELS/LONDON (Reuters) – The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.
The newly sworn-in FDA Commissioner told agency staff he hopes to speed lower cost generics to market and increase competition, particularly for complex drug products and biologics. http://www.biopharmadive.com/news/gottlieb-fda-drug-prices-generics-lower-cost/442824/
(Reuters) – French drugmaker Sanofi has pledged to peg U.S. drug price rises to below healthcare inflation in a move that limits increases for any product this year to 5.4 percent, unless there are exceptional circumstances.